GlassScriptPhysician profile
Susan Shey
NPI 1275988123
$6,391.22
in general payments reported to CMS, 2019-2025
39 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.38 · 2023: $1,516 · 2024: $2,314 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,284 · Education: $7.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,284.14 |
| Education | $7.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,077.06 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $783.44 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Insulet Corporation | $449.15 | 2023-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $383.45 | 2023-2025 | Gvoke Hypopen |
| Amgen INC. | $378.07 | 2021-2025 | Tepezza, Repatha, Repatha |
| Abbott Laboratories | $360.24 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.49 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $318.54 | 2023-2025 | |
| Mannkind Corporation | $284.06 | 2023-2025 | Afrezza |
| Abbvie INC. | $239.73 | 2024-2025 | |
| Dexcom, INC. | $231.36 | 2023-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $201.90 | 2023-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $167.67 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $131.53 | 2023-2025 | Strensiq |
| Soleno Therapeutics, INC. | $129.65 | 2025 | Vykat Xr |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $104.48 | 2024-2025 | Resmetirom, Rezdiffra |
| Tandem Diabetes Care, INC. | $90.95 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $75.56 | 2023-2025 | Tirosint, Licart, Tirosint |
| Medtronic, INC. | $66.80 | 2024 | Minimed 780g |
| Beta Bionics, INC. | $60.28 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sanofi-Aventis U.S. LLC | $56.02 | 2024-2025 | |
| Alvogen INC | $48.20 | 2023 | Teriparatide |
| Ascensia Diabetes Care US INC. | $45.19 | 2024 | |
| Glaxosmithkline, LLC. | $39.46 | 2025 | Arexvy, Shingrix |
| Sequel Med Tech, LLC | $29.03 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $28.68 | 2024 | Signifor Lar, Isturisa |
| Rhythm Pharmaceuticals, INC. | $27.82 | 2025 | Imcivree |
| Otsuka America Pharmaceutical, INC. | $25.50 | 2023 | Nuedexta |
| Astrazeneca Pharmaceuticals LP | $24.66 | 2021 | |
| Boston Scientific Corporation | $22.69 | 2025 | General - Pain Management |
| Amphastar Pharmaceuticals, INC. | $21.51 | 2025 | |
| Merck Sharp & Dohme LLC | $21.47 | 2025 | Gardasil 9, Capvaxive |
| Radius Health, INC. | $20.46 | 2023 | Tymlos |
| Zealand Pharma US, INC. | $20.35 | 2021 | |
| Horizon Therapeutics Plc | $19.61 | 2023 | Tepezza |
| Pfizer INC. | $17.89 | 2023 | |
| Lifescan, INC. | $17.45 | 2021 | |
| Exact Sciences Corporation | $17.05 | 2023 | Cologuard Collection Kit |
| Theracosbio, LLC | $16.77 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Shey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.